Cargando…

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line

The effects of 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline, on up-regulation of the MDR1 gene in the low-level multidrug resistant (MDR) cell line CEM/A7R were compared at similar concentrations (IC(10), IC(50)and IC(90)) over a short time exposure (4 and 24 h)....

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, X F, Slater, A, Rischin, D, Kantharidis, P, Parkin, J D, Zalcberg, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362657/
https://www.ncbi.nlm.nih.gov/pubmed/10070877
http://dx.doi.org/10.1038/sj.bjc.6990133
_version_ 1782153507635200000
author Hu, X F
Slater, A
Rischin, D
Kantharidis, P
Parkin, J D
Zalcberg, J
author_facet Hu, X F
Slater, A
Rischin, D
Kantharidis, P
Parkin, J D
Zalcberg, J
author_sort Hu, X F
collection PubMed
description The effects of 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline, on up-regulation of the MDR1 gene in the low-level multidrug resistant (MDR) cell line CEM/A7R were compared at similar concentrations (IC(10), IC(50)and IC(90)) over a short time exposure (4 and 24 h). The chemosensitivity of each drug was determined by a 3-day cell growth inhibition assay. Compared with epirubicin (EPI), IDA and MX2 were 17- and eightfold more effective in the CEM/A7R line respectively. No cross-resistance to 5-FU was seen in the CEM/A7R line. Verapamil (5 μM) and PSC 833 (1 μM), which dramatically reversed resistance to EPI in the CEM/A7R line, had no sensitizing effect on the resistance of this line to MX2, but slightly decreased resistance to IDA. The sensitivity to 5-FU was unchanged by these modulators. The induction of MDR1 mRNA expression by IDA, MX2 and 5-FU was analysed by Northern blotting and semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative level of MDR1 expression was expressed as a ratio of MDR1 mRNA to the internal RNA control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). IDA, MX2 and 5-FU differentially up-regulated MDR1 mRNA in the CEM/A7R line in a dose-dependent manner. Both IDA and MX2 induced MDR1 expression within 4 h. 5-FU up-regulated MDR1 expression only when drug exposure was prolonged to 24 h. Based on MRK 16 binding, flow cytometric analysis of P-glycoprotein (Pgp) expression paralleled the increase in MDR1 mRNA levels. For the three anthracyclines, the increase in MDR1 expression was stable in cells grown in the absence of drug for more than 3 weeks after drug treatment. The induction of MDR1 expression by 5-FU was transient, associated with a rapid decrease in the increased Pgp levels which returned to baseline 72 h after the removal of 5-FU. This study demonstrates that MDR1 expression can be induced by analogues of anthracyclies not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period. © 1999 Cancer Research Campaign
format Text
id pubmed-2362657
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23626572009-09-10 Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line Hu, X F Slater, A Rischin, D Kantharidis, P Parkin, J D Zalcberg, J Br J Cancer Regular Article The effects of 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline, on up-regulation of the MDR1 gene in the low-level multidrug resistant (MDR) cell line CEM/A7R were compared at similar concentrations (IC(10), IC(50)and IC(90)) over a short time exposure (4 and 24 h). The chemosensitivity of each drug was determined by a 3-day cell growth inhibition assay. Compared with epirubicin (EPI), IDA and MX2 were 17- and eightfold more effective in the CEM/A7R line respectively. No cross-resistance to 5-FU was seen in the CEM/A7R line. Verapamil (5 μM) and PSC 833 (1 μM), which dramatically reversed resistance to EPI in the CEM/A7R line, had no sensitizing effect on the resistance of this line to MX2, but slightly decreased resistance to IDA. The sensitivity to 5-FU was unchanged by these modulators. The induction of MDR1 mRNA expression by IDA, MX2 and 5-FU was analysed by Northern blotting and semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative level of MDR1 expression was expressed as a ratio of MDR1 mRNA to the internal RNA control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). IDA, MX2 and 5-FU differentially up-regulated MDR1 mRNA in the CEM/A7R line in a dose-dependent manner. Both IDA and MX2 induced MDR1 expression within 4 h. 5-FU up-regulated MDR1 expression only when drug exposure was prolonged to 24 h. Based on MRK 16 binding, flow cytometric analysis of P-glycoprotein (Pgp) expression paralleled the increase in MDR1 mRNA levels. For the three anthracyclines, the increase in MDR1 expression was stable in cells grown in the absence of drug for more than 3 weeks after drug treatment. The induction of MDR1 expression by 5-FU was transient, associated with a rapid decrease in the increased Pgp levels which returned to baseline 72 h after the removal of 5-FU. This study demonstrates that MDR1 expression can be induced by analogues of anthracyclies not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period. © 1999 Cancer Research Campaign Nature Publishing Group 1999-02 /pmc/articles/PMC2362657/ /pubmed/10070877 http://dx.doi.org/10.1038/sj.bjc.6990133 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Hu, X F
Slater, A
Rischin, D
Kantharidis, P
Parkin, J D
Zalcberg, J
Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
title Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
title_full Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
title_fullStr Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
title_full_unstemmed Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
title_short Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
title_sort induction of mdr1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362657/
https://www.ncbi.nlm.nih.gov/pubmed/10070877
http://dx.doi.org/10.1038/sj.bjc.6990133
work_keys_str_mv AT huxf inductionofmdr1geneexpressionbyanthracyclineanaloguesinahumandrugresistantleukaemiacellline
AT slatera inductionofmdr1geneexpressionbyanthracyclineanaloguesinahumandrugresistantleukaemiacellline
AT rischind inductionofmdr1geneexpressionbyanthracyclineanaloguesinahumandrugresistantleukaemiacellline
AT kantharidisp inductionofmdr1geneexpressionbyanthracyclineanaloguesinahumandrugresistantleukaemiacellline
AT parkinjd inductionofmdr1geneexpressionbyanthracyclineanaloguesinahumandrugresistantleukaemiacellline
AT zalcbergj inductionofmdr1geneexpressionbyanthracyclineanaloguesinahumandrugresistantleukaemiacellline